Trial Profile

A Double Blind, Dose Response Phase II, Multicentre Study of Radium 223 (Alpharadin) for the Palliation of Painful Bone Metastases in Hormone Refractory Prostate Cancer Patients

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Radium 223 chloride (Primary)
Indications Adenocarcinoma; Bone metastases; Cancer pain; Prostate cancer
Focus Therapeutic Use
Sponsors Bayer

Most Recent Events

17 Dec 2012 New source identified and integrated (German Clinical Trials Register; DRKS00004104).
15 Feb 2012 Results published in the European Journal of Cancer.
17 Sep 2010 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com